An observational study in Cancer, Drug Toxicity and Atrial Fibrillation, sponsored by University Hospital, Caen. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by University Hospital, Caen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →University Hospital, Caen is the lead sponsor of 515 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a cancer will defined as patients with confirmed cancer other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia.
Active cancer will be defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, and an anticancer treatment given at the time of enrollment or during 6 months before enrollment (according to Agnelli et al. NEJM 2020).
AF patients will be both patients with incident AF (first AF episode diagnosed after cancer diagnosis) and those with prevalent AF (AF recurrence occurring after cancer diagnosis and a first AF episode prior to cancer diagnosis)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
Occurrence of major cardiovascular events and death of any cause at 1 year
Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients with atrial fibrillation.
Time frame: from inclusion in the registry to 1 year of follow-up
Occurrence of major cardiovascular events and death of any cause at 1 year in prevalent and incident AF patients
Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients according to the AF type (prevalent or incident).
Time frame: from inclusion in the registry to 1 year of follow-up
Description of the population of active cancer patients experiencing atrial fibrillation (in both prevalent and incidence AF patients).
Description of the population of active cancer patients experiencing atrial fibrillation. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
Time frame: at the inclusion in the registry
Description of the management of atrial fibrillation in cancer patients (in both prevalent and incidence AF patients).
Description of the management (anticoagulants, rhythm or rate control) of atrial fibrillation in cancer patients
Time frame: from inclusion in the registry to 1 year of follow-up
Description of the population of active cancer patients having a major cardiovascular event
Description of the population of patients having a major cardiovascular event among cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying risk factors associated with major cardiovascular events and all cause mortality occurrence
Identifying risk factors (clinical, EKG, biological, echocardiography) of major cardiovascular events and all cause mortality in cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying factors associated with atrial fibrillation recurrence
Identifying factors (clinical, EKG, biological, echocardiography) of atrial fibrillation recurrence in cancer patients
Time frame: from inclusion in the registry to 1 year of follow-up
Occurrence of major and clinically relevant non-major bleedings (2005 ISTH definition)
Occurrence of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation.
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying risk factors associated with major and clinically relevant non-major bleedings (2005 ISTH definition)
Identifying risk factors (clinical, EKG, biological, echocardiography) of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
Plan to share: Undecided
Started Sep 2021 (actual). Primary completion is estimated for Sep 2025, 48 months after the start.
Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 48 months is below that.
Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.